Regenxbio Inc. is a biotechnology company focused on gene therapy. Its core products include gene therapies for various genetic diseases, particularly in the areas of ophthalmology and neurology. The company’s major business segments involve the development of its proprietary NAV Technology Platform, which is designed to deliver therapeutic genes to target cells. Main revenue sources primarily stem from collaborations and licensing agreements with other pharmaceutical companies.
The investment profile of Regenxbio is more aligned with growth investors, given its focus on innovative gene therapies and potential for future revenue generation through partnerships. However, the high risk associated with its current financial performance and volatility may deter conservative investors. The stock may appeal to those with a longer investment horizon who are willing to accept higher risk for potential future gains.
| Datum | Vorher | Nachher | Grund |
|---|---|---|---|
| 2026-05-16 02:51 | Halten | Verkaufen | scenario_deterioration |
| 2026-05-08 15:28 | — | Halten | Weak fundamentals, positive short-term momentum observed. |
| 2026-05-07 02:47 | Verkaufen | Halten | Компания показывает положительную динамику за последние недели, однако негативные показатели EPS и низкий уровень доходов указывают на высокие риски. Рекомендуется удерживать акции до получения более ясных сигналов о вос |
| Datum | Analyst | Action | Ziel | Preis damals |
|---|---|---|---|---|
| 2026-05-15 12:29 | Morgan Stanley | Ziel gesenkt | 17 → 16 | 6.3097 |
| 2026-05-15 09:00 | Barclays | Ziel gesenkt | 37 → 12 | 6.245 |
| 2026-03-09 10:13 | H.C. Wainwright | Ziel gesenkt | 32 → 30 | 10.38 |
